Citius Pharmaceuticals, Inc.
CTXR
$0.56
-$0.03-5.65%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 72.36% | 0.56% | -2.39% | 5.18% | 19.75% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.67% | -4.26% | -8.26% | 0.17% | 9.91% |
| Operating Income | -30.62% | 13.50% | 8.26% | -0.17% | -9.91% |
| Income Before Tax | -28.77% | 4.99% | 0.43% | -9.07% | -19.66% |
| Income Tax Expenses | -31.23% | 51.80% | 83.47% | 62.60% | 41.74% |
| Earnings from Continuing Operations | -27.64% | 4.01% | -0.80% | -9.87% | -20.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 563.09% | 270.81% | 703.62% | -- | -- |
| Net Income | -9.88% | 9.55% | 4.36% | -5.15% | -16.16% |
| EBIT | -30.62% | 13.50% | 8.26% | -0.17% | -9.91% |
| EBITDA | -25.28% | 14.84% | 8.26% | -0.17% | -9.92% |
| EPS Basic | 54.79% | 49.77% | 35.54% | 18.67% | 3.11% |
| Normalized Basic EPS | 56.24% | 54.31% | 40.73% | 24.96% | 10.74% |
| EPS Diluted | 54.79% | 49.77% | 35.54% | 19.27% | 5.76% |
| Normalized Diluted EPS | 56.24% | 54.31% | 40.73% | 24.96% | 10.74% |
| Average Basic Shares Outstanding | 138.18% | 107.83% | 64.55% | 31.81% | 19.95% |
| Average Diluted Shares Outstanding | 138.18% | 107.83% | 64.55% | 31.81% | 19.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |